Phase 2 N=57 Thromboxane Receptor Antagonist to Improve Endothelial Function
Cardiovascular Diseases · Vascular Dilation
Primary: Change in Reactive Hyperemia Index (RHI) — -0.01; 0.21 percentage index change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,050 Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2
Immunization Against COVID-19
Primary: The Number of Laboratory-confirmed SARS-CoV-2 Infections. — 7; 22 Participants — p=0.0046
N/A N=42 Improving Adherence in Nonadherent Kidney Transplant Patients
Medication Adherence · Kidney Transplantation
Primary: Change in Number of Patients Being Adherent/Non-aherent After the Intervention — 15; 30; 34; 35 Participants
Phase 1 N=4 Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
Tuberculosis · Tuberculosis, Pulmonary · Bacterial Infections Respiratory
Primary: Rates and Routes of Excretion — 331; 162 mg eq
N/A N=50 Pilot Clinical Investigation Evaluating the Safety and Performance of RGn550 in Treating Sportspeople Suffering From Acute Concussion Syndrome
Acute Concussion Syndrome
Primary: Incidence of RGn550's Adverse Device Effects (ADEs) — 10; 10 Participants
N/A N=197 The WISE (Weightloss Intervention Surgical Effects) Brain Study
Diabetes · Weightloss
Primary: Change in BOLD fMRI Signal — 0.10; 0.08; 0.18; -0.01 Connectivity Fisher-z transformation — p=<0.01
Phase 3 N=606 Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Crohn Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150 — 29.8; 30.5 percentage of participants — p=0.8125
N/A N=20 Innovations in Clinical Care of CE Approved Nucleus Cochlear Implant Recipients
Hearing Loss
Primary: Mean Difference Between Standard and Novel Fitting Method for Monosyllabic Word Scores in Quiet — 3.8 difference in percentage correct answers
Phase 1 N=54 Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)
Bacterial Infection
Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 1; 1; 0 Participants
N/A N=160 NexGen TM Tibia Clinical Outcomes Study
Osteoarthritis · Rheumatoid Arthritis · Traumatic Arthritis
Primary: Radiograph Assessment of Progressive Tibial Radiolucencies — 82; 55; 0; 0 Knees
Phase 3 N=292 A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
Platysma Prominence
Primary: Number of Participants With Adverse Events — 33; 74; 46; 26 Participants
Phase 4 N=23 GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
Glucose Intolerance · Overweight and Obesity · Drug Effect
Primary: Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue) — 7.88; 7.67 natural log(arbitrary units)
N/A N=32 Effects of PSAPs on Speech Processing
Hearing Loss, Age-Related
Primary: Percentage of Correct Responses With and Without PSAPs — 85.2; 84.0 percentage of correct answers — p=0.03
Phase 2 N=32 Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Invasive Bladder Cancer
Primary: Proportion of Patients With Pathological Response — 26; 2 Participants
Phase 3 N=509 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 — 32.2; 53.8; 52.0 percentage of…